This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Cristoph KeBler, MD
Berlin, Germany

Arch Ophthalmol. 1994;112(10):1277.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the December 1993 issue of the ARCHIVES, a case report about possible uveitis secondary to metipranolol (OptiPranolol) therapy was published.¹

I would like to comment on a statement in this case report: "The multidose preparations of metipranolol have been subsequently withdrawn from the European market."

As a manufacturer of metipranolol eye drops worldwide, I would like to point out that only the multidose preparations of metipranolol (Glauline) have been withdrawn from the market in England. Single-dose units are still available in England. In other European and non-European countries worldwide, multidose preparations of metipranolol are still available. To avoid confusion and uncertainty in patients and ophthalmologists in Europe, I think it is important to make this information clear. In addition, similar reports of uveitis have been published for other β-blockers as well.² . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?